| pubmed-article:8452480 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8452480 | lifeskim:mentions | umls-concept:C2239176 | lld:lifeskim |
| pubmed-article:8452480 | lifeskim:mentions | umls-concept:C1882726 | lld:lifeskim |
| pubmed-article:8452480 | lifeskim:mentions | umls-concept:C0014930 | lld:lifeskim |
| pubmed-article:8452480 | lifeskim:mentions | umls-concept:C0039286 | lld:lifeskim |
| pubmed-article:8452480 | lifeskim:mentions | umls-concept:C0752229 | lld:lifeskim |
| pubmed-article:8452480 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:8452480 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:8452480 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:8452480 | pubmed:dateCreated | 1993-4-15 | lld:pubmed |
| pubmed-article:8452480 | pubmed:abstractText | The effects of equimolar doses of the triphenylethylene antiestrogens tamoxifen and toremifene on female Sprague-Dawley rat liver were studied in a 52-week toxicity study which included a 13-week recovery period. Liver tumors were found in four out of five rats at the highest dose level of tamoxifen (45 mg/kg per day) after 52 weeks of dosing, and these appeared to be hepatocellular carcinomas in three rats. After the 13-week recovery period all surviving rats in the highest tamoxifen dose group had large liver tumors (diameter up to 2 cm) which appeared to be hepatocellular carcinomas in five out of six rats. No tumor was observed in the toremifene-treated rats (48 mg/kg per day) either after 52 weeks of dosing or after the recovery period. Electron microscopic morphometric analysis after 52 weeks of dosing revealed that at the tamoxifen high dose level, the volume densities of the peroxisomes, mitochondria, and residual bodies were elevated in the nonneoplastic hepatocytes of the rats. In the neoplastic hepatocytes of the tamoxifen-treated rats the volume density of nuclei was slightly elevated. The slight proliferation of peroxisomes and mitochondria might be related to tumor development in the tamoxifen treated rats. | lld:pubmed |
| pubmed-article:8452480 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8452480 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8452480 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8452480 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8452480 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8452480 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8452480 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8452480 | pubmed:issn | 0340-5761 | lld:pubmed |
| pubmed-article:8452480 | pubmed:author | pubmed-author:NieminenLL | lld:pubmed |
| pubmed-article:8452480 | pubmed:author | pubmed-author:PayneB JBJ | lld:pubmed |
| pubmed-article:8452480 | pubmed:author | pubmed-author:HirsimäkiYY | lld:pubmed |
| pubmed-article:8452480 | pubmed:author | pubmed-author:HirsimäkiPP | lld:pubmed |
| pubmed-article:8452480 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8452480 | pubmed:volume | 67 | lld:pubmed |
| pubmed-article:8452480 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8452480 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8452480 | pubmed:pagination | 49-54 | lld:pubmed |
| pubmed-article:8452480 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:8452480 | pubmed:meshHeading | pubmed-meshheading:8452480-... | lld:pubmed |
| pubmed-article:8452480 | pubmed:meshHeading | pubmed-meshheading:8452480-... | lld:pubmed |
| pubmed-article:8452480 | pubmed:meshHeading | pubmed-meshheading:8452480-... | lld:pubmed |
| pubmed-article:8452480 | pubmed:meshHeading | pubmed-meshheading:8452480-... | lld:pubmed |
| pubmed-article:8452480 | pubmed:meshHeading | pubmed-meshheading:8452480-... | lld:pubmed |
| pubmed-article:8452480 | pubmed:meshHeading | pubmed-meshheading:8452480-... | lld:pubmed |
| pubmed-article:8452480 | pubmed:meshHeading | pubmed-meshheading:8452480-... | lld:pubmed |
| pubmed-article:8452480 | pubmed:meshHeading | pubmed-meshheading:8452480-... | lld:pubmed |
| pubmed-article:8452480 | pubmed:meshHeading | pubmed-meshheading:8452480-... | lld:pubmed |
| pubmed-article:8452480 | pubmed:meshHeading | pubmed-meshheading:8452480-... | lld:pubmed |
| pubmed-article:8452480 | pubmed:meshHeading | pubmed-meshheading:8452480-... | lld:pubmed |
| pubmed-article:8452480 | pubmed:meshHeading | pubmed-meshheading:8452480-... | lld:pubmed |
| pubmed-article:8452480 | pubmed:meshHeading | pubmed-meshheading:8452480-... | lld:pubmed |
| pubmed-article:8452480 | pubmed:meshHeading | pubmed-meshheading:8452480-... | lld:pubmed |
| pubmed-article:8452480 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8452480 | pubmed:articleTitle | Tamoxifen induces hepatocellular carcinoma in rat liver: a 1-year study with two antiestrogens. | lld:pubmed |
| pubmed-article:8452480 | pubmed:affiliation | Central University Hospital, Department of Pathology, Turku, Finland. | lld:pubmed |
| pubmed-article:8452480 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8452480 | pubmed:publicationType | Comparative Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8452480 | lld:pubmed |
